MAP2K7 and fibrosarcoma: Mitogen-activated protein kinase kinase (MEK) inhibitors have demonstrated efficacy in both arresting the cell cycle11 and preventing fibrosis through a rapidly accelerated fibrosarcoma (Raf)/MEK/extracellular signal-regulated kinase (ERK) pathway12,13.